Tirzepatide is a novel synthetic peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-agonist mechanism positions it at the forefront of type 2 diabetes and obesity research.
In scientific studies, Tirzepatide has been shown to:
-
Enhance insulin secretion and sensitivity, improving glycemic control in hyperglycemia models.
-
Reduce appetite and food intake, contributing to significant weight loss in metabolic syndrome research.
-
Delay gastric emptying, helping modulate postprandial glucose spikes.
-
Influence lipid metabolism, with improved HDL/LDL profiles in animal models.
Its combined incretin action delivers superior metabolic effects compared to GLP-1 agonists alone, making it a powerful compound for multifactorial metabolic disorder studies.
Reconstitution Instructions:
Reconstitute with BAC water. Refrigerate after reconstitution and use under sterile research conditions.
For research purposes only. Not for human consumption.
Reviews
There are no reviews yet.